Korro Bio
KRRO
Korro Bio (KRRO) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$2.74
- EPS estimate
- −$2.57
- EPS surprise
- −6.80%
- Revenue surprise
- +200.59%
- Revenue
- $1.5M
- Revenue estimate
- $485,712.00
- Reported
- Aug 12, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 12, 2025 | −$2.57 | −$2.74 | −6.80% | $1.5M | SEC |
| Q1 2025 | May 7, 2025 | −$2.58 | −$2.49 | +3.56% | $2.5M | SEC |
| Q4 2024 | Mar 18, 2025 | −$2.50 | −$2.24 | +10.40% | $2.3M | SEC |
| Q3 2024 | Nov 12, 2024 | −$2.53 | −$2.26 | +10.56% | $0.00 | SEC |
| Q2 2024 | Aug 13, 2024 | −$2.43 | −$2.43 | −0.06% | $0.00 | SEC |
| Q1 2024 | May 14, 2024 | −$2.38 | −$2.44 | −2.40% | $0.00 | SEC |
| Q4 2023 | Mar 26, 2024 | −$3.53 | −$4.01 | −13.46% | $0.00 | SEC |
| Q3 2023 | Nov 2, 2023 | −$1.45 | −$3.27 | −125.52% | $0.00 | SEC |
| Q2 2023 | Aug 10, 2023 | −$17.80 | −$15.00 | +15.71% | $0.00 | SEC |
| Q1 2023 | May 12, 2023 | −$21.00 | −$27.50 | −30.95% | $0.00 | SEC |
| Q4 2022 | Mar 10, 2023 | −$31.55 | −$24.50 | +22.35% | $0.00 | SEC |
| Q3 2022 | Nov 8, 2022 | −$28.50 | −$27.50 | +3.51% | $0.00 | SEC |
| Q2 2022 | Aug 9, 2022 | −$33.17 | −$30.50 | +8.04% | $0.00 | SEC |
| Q1 2022 | May 4, 2022 | −$31.80 | −$33.50 | −5.36% | $0.00 | SEC |
| Q4 2021 | Mar 15, 2022 | $7.64 | −$31.00 | −505.90% | $0.00 | SEC |
| Q3 2021 | Nov 15, 2021 | −$29.45 | −$36.50 | −23.94% | $0.00 | SEC |
| Q2 2021 | Aug 12, 2021 | −$25.43 | −$26.00 | −2.24% | $9.4M | SEC |
| Q1 2021 | May 13, 2021 | $6.88 | −$30.00 | −536.36% | $4.7M | SEC |
| Q4 2020 | Mar 29, 2021 | −$12.73 | −$15.00 | −17.86% | $9.9M | SEC |
| Q3 2020 | Nov 16, 2020 | −$13.88 | −$8.00 | +42.34% | $11.2M | SEC |
Quarterly revenue
Frequently asked questions
When did Korro Bio (KRRO) last report earnings?
Korro Bio last reported on Aug 12, 2025, covering fiscal Q2 2025.
Did KRRO beat earnings estimates?
No. Korro Bio reported EPS of −$2.74 for Q2 2025 against a −$2.57 estimate — a 6.80% miss.
How much revenue did KRRO report last quarter?
Korro Bio reported $1.5M in revenue for Q2 2025, against a consensus estimate of $485,712.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.